APA (7th ed.) Citation

M, K., S, C., R, S., B, P., J, S., E, C., . . . F, B. (2026). Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane. NPJ breast cancer, 12(1), . https://doi.org/10.1038/s41523-026-00909-0

Chicago Style (17th ed.) Citation

M, Kubeczko, et al. "Validation of the HER2DX Genomic Test in First-line Advanced HER2-positive Breast Cancer Treated with Trastuzumab, Pertuzumab, and Taxane." NPJ Breast Cancer 12, no. 1 (2026). https://doi.org/10.1038/s41523-026-00909-0.

MLA (9th ed.) Citation

M, Kubeczko, et al. "Validation of the HER2DX Genomic Test in First-line Advanced HER2-positive Breast Cancer Treated with Trastuzumab, Pertuzumab, and Taxane." NPJ Breast Cancer, vol. 12, no. 1, 2026, https://doi.org/10.1038/s41523-026-00909-0.